New executive comes with over 15 years of experience.
MikeWorldWide has tapped Ryan Lilly to serve as SVP and managing director of MWW Health, the firm’s healthcare public relations practice. According to the company, Lilly joins with 15 years of experience in building disruptive brands and driving meaningful thought leadership across the continuum of care. Previously, he worked to launch Matter Health, the healthcare division of Matter Communications.
"The healthcare space is highly complex and specialized yet universally relatable--one of the few markets that truly impacts every person on earth. We are living in a reputation-driven economy. As consumer expectations for companies continue to increase, all eyes are on the healthcare sector to make an impact on nearly every aspect of society and in every community," said Michael Kempner, founder, CEO, MikeWorldWide, in a company press release. "Ryan's experience in leading clients across the healthcare sector, coupled with a deep mastery of technology, makes him uniquely qualified to lead our healthcare team and guide healthcare clients through this period of rapid transformation and complexity, connecting the dots between the science, regulatory factors, and the patient experience in a way that builds trust and reputation for the companies driving transformation of the industry."
Reference: MikeWorldWide Taps Health Communications Expert Ryan Lilly to Lead Integrated Healthcare PR Practice, MWW Health. PR Newswire. August 16, 2023. Accessed August 23, 2023. https://www.prnewswire.com/news-releases/mikeworldwide-taps-health-communications-expert-ryan-lilly-to-lead-integrated-healthcare-pr-practice-mww-health-301901978.html
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.